Sara Carrillo De Albornoz, Alisa M Higgins, Dennis Petrie, Adam Irving, Laura Fanning, Robert Weinkove, Philip Crispin, Claire Dendle, Michael Gilbertson, Anna M Johnston, Anastazia Keegan, Dominic Pepperell, Humphrey W Pullon, John Reynolds, Tina van Tonder, Judith Trotman, Neil Waters, Cameron Wellard, Helen Weston, Orla Morrissey, Erica M Wood, Zoe McQuilten
Patients with hematological malignancies are at high risk of developing hypogammaglobulinemia (HGG) and infections. Immunoglobulin (Ig) is one recommended option to prevent these infections, but it is expensive and its cost-effectiveness compared with other prevention strategies remains unknown. We conducted a trial-based economic evaluation from the Australian healthcare system perspective to estimate the 12-month cost-effectiveness of prophylactic Ig versus prophylactic antibiotics in 63 adults with HGG and hematological malignancies participating in the RATIONAL feasibility trial...
March 14, 2024: Blood Advances